Phase 2 Evidence and Impact Analysis
All articles were classified from PubMed abstracts only (no full text reviewed). Scores reflect this limitation. Non-human studies are capped at ≤5 on Clinical Relevance. Low/medium classification_confidence articles are scored conservatively.
Article 1 — Acmopatide (CT-868) Phase 2 RCT in T1D (PMID 42949535)
⚪ PROMISING_PRELIMINARY | Phase 2 RCT | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First "fully biased" GLP-1/GIP dual agonist tested in T1D with overweight/obesity — mechanistically distinct from existing agents; no DKA signal is notable |
| Clinical Relevance | 8 | T1D + obesity is a growing, under-addressed combination; glycemic + weight benefit without DKA or severe hypoglycemia addresses two major unmet needs |
| Population Reach | 7 | ~8.7M adults with T1D globally; subset with overweight/obesity is large and growing |
| Implementation Speed | 6 | Phase 2 complete; Phase 3 required before regulatory filing — realistically 4–7 years |
| Evidence Strength | 7 | Phase 2 RCT, double-blind, multicenter; 111 participants limits precision; 16-week duration short for metabolic outcomes |
Key quantitative result: Clinically meaningful weight loss + improved glycemic control; no DKA or severe hypoglycemia (specific effect sizes not available from abstract). External validation: None yet; single Phase 2 study. Main limitation: Abstract-only; 16-week duration; small N (111); no Phase 3 data. Equity: People with T1D + obesity — often younger adults, lower SES groups — have had limited adjunct therapy options. GLP-1 agents have been largely studied in T2D. This addresses a real gap. Access will depend on pricing and insurance coverage. Evidence Maturity (revised): Validated (Phase 2) → on pathway; not yet practice-changing.
Article 2 — Rebisufligene etisparvovec for MPS IIIA (PMID 42951601)
⬜ STANDARD | Regulatory evidence review | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First approved disease-modifying therapy for MPS IIIA (Sanfilippo syndrome type A), a uniformly fatal neurodegenerative disease with no prior approved treatment |
| Clinical Relevance | 9 | For the relevant rare population — children with MPS IIIA — this is transformative: first therapy to alter natural history. Judged relative to unmet need |
| Population Reach | 4 | Ultra-rare: ~1 in 70,000–100,000 births; but severity and zero prior options make unmet need extreme |
| Implementation Speed | 4 | Already approved (regulatory review article); implementation limited by specialist center capacity, manufacturing, cost, newborn screening gaps |
| Evidence Strength | 5 | Open-label, 17 treated patients vs. 27 external natural-history controls; no randomization; modeled cognitive outcomes; classification_confidence = medium |
Key quantitative result: Improved modeled cognitive outcomes; lowered CSF heparan sulfate. Serious adverse events including substantial liver enzyme elevations noted. External validation: Not replicated; this is the approval-supporting dataset. Main limitation: Tiny uncontrolled open-label study; external controls introduce confounding; modeled (not directly measured) cognitive endpoints; liver toxicity requires long-term surveillance. classification_confidence = medium. Equity: Children diagnosed early enough to preserve neurodevelopmental function benefit most. Access is profoundly unequal globally — newborn screening is not universal and the drug will be extremely costly. Low-income countries and unscreened populations will be largely excluded. Evidence Maturity (confirmed): Potentially Practice-Changing — within its ultra-rare population.
Article 3 — Chatbot Cognitive Training RCT in Older Adults (PMID 42950244)
⬜ STANDARD | Single-blind RCT | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Chatbot-delivered cognitive training is incremental over prior digital cognitive training literature; white-matter imaging endpoint adds some novelty |
| Clinical Relevance | 5 | Cognitively unimpaired older adults — prevention application; episodic memory improvement is meaningful but no dementia incidence data |
| Population Reach | 7 | Aging population globally; scalable technology if validated |
| Implementation Speed | 7 | Chatbot tools are already widely accessible; regulatory barriers low for non-diagnostic cognitive tools |
| Evidence Strength | 6 | Single-blind RCT (n=72); short duration (12 weeks); limited blinding possible for behavioral intervention; abstract only |
Key quantitative result: Improved episodic memory and reduced decline in selected white-matter measures vs. no intervention. External validation: None; single-site or limited multicenter. Main limitation: Small N; single-blind; 12 weeks is insufficient to draw conclusions about dementia prevention; no active control condition reported. Equity: Digital literacy and device access create equity gaps among the oldest-old, lower-SES, and rural populations. Evidence Maturity: Validated (RCT) but underpowered — closer to Exploratory for prevention claims.
Article 4 — CAR-T Referral Patterns in R/R LBCL, US (PMID 42950247)
🟡 UNDERSERVED_POPULATION | Retrospective claims cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Access gap for CAR-T is known; large real-world quantification adds granularity but not conceptual novelty |
| Clinical Relevance | 7 | Directly actionable for health systems, payers, and referring oncologists; quantifies a care gap with survival implications |
| Population Reach | 6 | ~20,000 new DLBCL/R-R LBCL cases per year in US; access gap affects a meaningful proportion |
| Implementation Speed | 6 | Health system and referral pattern changes are feasible in near term if will exists |
| Evidence Strength | 6 | Large real-world cohort (n=8,959) with claims data; retrospective; selection bias; no overall survival endpoint; classification_confidence = medium |
Key quantitative result: 20% referral rate, 15% treatment rate among eligible patients; CAR-T recipients had longer time to next treatment or death. External validation: US claims only; may not generalize internationally. Main limitation: Claims data limitations; no information on reasons for non-referral; potential confounding by performance status. Equity: Disparities by geography (rural vs. urban), insurance type, race/ethnicity likely but not fully characterized in abstract. This is precisely the underserved population concern flagged. Evidence Maturity: Validated (observational) — but for policy/system change, not clinical practice.
Article 5 — Radiotherapy Omission in High-Risk Early Hodgkin Lymphoma (PMID 42950253)
⬜ STANDARD | Retrospective multicenter propensity-matched cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Ongoing debate about radiation omission in HL is established; this adds real-world propensity-matched data |
| Clinical Relevance | 7 | Active clinical controversy; directly addresses current practice patterns for a curable disease where late toxicity matters |
| Population Reach | 5 | ~9,000 new HL cases/year in US; subset with bulky/interim-PET-positive disease |
| Implementation Speed | 6 | Data informing existing clinical decision-making — could influence guidelines; no new intervention needed |
| Evidence Strength | 6 | Multicenter, propensity-matched (n=810/480 matched); retrospective; abstract only; classification_confidence = medium |
Key quantitative result: Radiotherapy omission → inferior disease control in bulky or interim-PET-positive disease; OS similar; late toxicity higher with combined therapy. Main limitation: Retrospective; residual confounding despite matching; OS not different (underpowered?); abstract only. Equity: Young patients (HL peaks 20s–30s) where late toxicity of radiation is particularly important. Evidence Maturity: Validated (observational); contributes to but does not resolve the debate.
Article 6 — Prescription-Free Chlamydia Screening in France (PMID 42950355)
⬜ STANDARD | Retrospective laboratory network study | Triage score: 7 | Unsolicited find
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Prescription-free STI screening is established policy in several countries; this is implementation/effectiveness data at scale |
| Clinical Relevance | 6 | Directly supports expansion of simplified screening models; actionable for public health policy |
| Population Reach | 8 | Young adults (15–24) are the primary STI risk group; chlamydia affects ~130M people/year globally |
| Implementation Speed | 7 | Simplified screening is already in place in France; findings support extension or replication elsewhere |
| Evidence Strength | 6 | Very large dataset (n=543,607 screenings); retrospective; laboratory network; no clinical outcome data; positivity rates only; classification_confidence = medium |
Key quantitative result: High positivity in young adults; multisite sampling identified infections missed by urogenital-only testing. Main limitation: No clinical outcomes; retrospective; France-specific healthcare context. Equity: Prescription-free testing specifically addresses access barriers for young adults and those without established primary care — a genuine equity win. Evidence Maturity: Validated (implementation data at scale).
Article 7 — ctDNA Risk Stratification in Resectable Colorectal Oligometastases (PRECISION) (PMID 42950585)
⬜ STANDARD | Prospective multicenter biomarker cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Dual use of pretreatment genomic profile AND postoperative MRD ctDNA in oligometastatic CRC is a clinically meaningful combination not yet standard |
| Clinical Relevance | 7 | Could directly change adjuvant therapy decisions after resection of colorectal metastases |
| Population Reach | 6 | CRC is common (~1.9M cases/year globally); oligometastatic subset eligible for surgery is significant |
| Implementation Speed | 5 | ctDNA platforms increasingly available but not uniformly; requires prospective validation before guideline adoption |
| Evidence Strength | 6 | Prospective multicenter (n=118); hypothesis-generating size; abstract only; evidence_maturity = Exploratory |
Key quantitative result: Poor pretreatment genomic profile and postoperative MRD independently predicted shorter recurrence-free survival and time to surgical failure. Main limitation: N=118 is underpowered for subgroup analysis; no intervention arm; abstract only. Equity: ctDNA assays add cost — access disparities are real in lower-resource settings. Evidence Maturity (revised): Exploratory — prospective but hypothesis-generating.
Article 8 — ctDNA/CTC Biomarker Analysis in TALAPRO-2 (Prostate Cancer) (PMID 42950862)
⬜ STANDARD | Exploratory biomarker analysis nested in Phase 3 RCT | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Combining baseline ctDNA burden AND early clearance as prognostic biomarkers in a Phase 3 mCRPC trial adds meaningful precision medicine data |
| Clinical Relevance | 7 | Could inform patient selection and monitoring decisions in mCRPC; Lancet Oncology publication adds credibility |
| Population Reach | 6 | mCRPC affects ~500,000 men globally; subset on talazoparib+enzalutamide |
| Implementation Speed | 5 | Biomarker is exploratory; requires prospective validation before clinical use; ctDNA platforms needed |
| Evidence Strength | 7 | Nested in Phase 3 RCT (n=805 randomized); exploratory analysis so not powered for biomarker; abstract only |
Key quantitative result: Baseline ctDNA burden and early ctDNA/CTC clearance strongly prognostic for radiographic PFS. Main limitation: Exploratory analysis not pre-specified as primary; abstract only; no actionability demonstrated yet. Equity: mCRPC disproportionately affects Black men; whether ctDNA prognostic performance is consistent across racial groups is unknown. Evidence Maturity: Validated (nested in Phase 3) but biomarker analysis remains Exploratory.
Article 9 — SGLT2 Inhibitor Comparative Kidney Outcomes (Target Trial Emulation) (PMID 42951018)
⬜ STANDARD | Target-trial emulation | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Comparative effectiveness within SGLT2i class is an active but not novel research question; target-trial emulation approach adds methodological rigor |
| Clinical Relevance | 8 | Directly addresses prescribing choice among three widely used agents; kidney outcomes matter enormously in T2D |
| Population Reach | 9 | T2D affects ~537M adults globally; most are potential SGLT2i candidates |
| Implementation Speed | 7 | Drugs are already on market; prescriber behavior could shift relatively quickly if findings are replicated |
| Evidence Strength | 6 | Large (n=131,434 weighted); target-trial emulation is rigorous but not equivalent to RCT; residual confounding; abstract only; classification_confidence = medium |
Key quantitative result: Dapagliflozin and empagliflozin associated with modestly fewer major adverse kidney events than canagliflozin. Main limitation: Observational; residual confounding; "modest" difference needs quantification; excludes CKD stage 3+ (high-risk patients who need guidance most). Equity: Excludes patients with advanced CKD — those who stand to benefit most from kidney protection. Evidence Maturity: Validated (large observational); hypothesis-generating for prescribing.
Article 10 — IDH2 p.R172 Mutation and Transplant Outcomes in AML/MDS (PMID 42951113)
⬜ STANDARD | Retrospective multicenter cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | IDH2 subtype-specific transplant outcome differentiation (R172 vs. R140) is clinically undercharacterized; "zero relapse" signal is striking |
| Clinical Relevance | 6 | Could influence pre- and post-transplant IDH inhibitor use and monitoring decisions |
| Population Reach | 4 | IDH2-mutated AML/MDS is a specific molecular subset (~15–20% of AML); R172 is the minority subtype |
| Implementation Speed | 6 | Molecular subtyping is already performed; clinical implications feasible if validated in larger cohorts |
| Evidence Strength | 5 | Small N (n=101); retrospective; multivariate analysis limited by sample size; abstract only; classification_confidence = medium |
Key quantitative result: IDH2 p.R172 independently associated with zero observed relapse, better PFS and OS after allo-HCT. Main limitation: N=101 overall; R172 subgroup even smaller; retrospective confounding; abstract only. Equity: Specialized transplant centers may have better molecular subtyping; rural/resource-limited patients may not access this nuance. Evidence Maturity: Exploratory-to-Validated — retrospective with hypothesis-generating signal; needs prospective confirmation.
Article 11 — ML Model for Drug-Induced QTc Prolongation Risk (PMID 42951254)
⚪ PROMISING_PRELIMINARY | Retrospective ML with external validation | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ML prediction of drug-induced QTc prolongation is an active field; external validation is a relative strength |
| Clinical Relevance | 7 | Drug-induced QTc prolongation is a common inpatient safety problem; a risk-stratification tool could reduce preventable arrhythmias |
| Population Reach | 7 | Essentially all hospitalized patients receiving QT-prolonging medications; very broad |
| Implementation Speed | 5 | Integration into EHR decision support feasible but requires validation, workflow design, institutional buy-in |
| Evidence Strength | 6 | External validation cohort (n=150) is very small; AUC 0.864 but recall 0.650 means 35% of true cases missed; abstract only |
Key quantitative result: External validation AUC 0.864; recall 0.650. Main limitation: External validation cohort is tiny (n=150); 35% miss rate is clinically significant for a safety application; single-center external validation. Equity: Standard hospital EHR data; broadly applicable if validated. Existing disparities in QT monitoring may be reflected in training data. Evidence Maturity: Validated but limited by small external validation — closer to Exploratory for clinical deployment.
Article 12 — Real-World Tirzepatide Weight Loss at 12 Months (PMID 42951303)
⬜ STANDARD | Retrospective real-world observational cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Tirzepatide real-world weight loss is increasingly published; GLP-1-naive vs. experienced comparison adds modest incremental value |
| Clinical Relevance | 7 | Real-world confirmation of trial-level weight loss (19.3% GLP-1 naive, 13.1% GLP-1 experienced) is directly relevant to prescribing |
| Population Reach | 8 | Obesity affects ~1 billion adults globally; tirzepatide is widely prescribed |
| Implementation Speed | 8 | Drug is on market; data directly applicable to current clinical practice |
| Evidence Strength | 5 | Small N with documented weights (n=353); commercially insured only; persistence bias (only those who stayed on drug counted); retrospective; abstract only; classification_confidence = medium |
Key quantitative result: Mean 19.3% weight loss (GLP-1 naive) and 13.1% (GLP-1 experienced) at 12 months. Main limitation: Severe persistence bias (only those who continued 12 months counted); commercially insured population not generalizable; no comparator arm. Equity: Commercially insured adults only — explicitly excludes uninsured and Medicaid/Medicare populations where obesity burden is highest. Evidence Maturity: Validated (real-world) but methodologically limited.
Article 13 — 3D Radiotherapy Dose Prediction (AAPM Challenge) (PMID 42949277)
⬜ STANDARD | ML development and held-out validation | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Challenge-winning framework for cross-site dose prediction is technically noteworthy; clinical translation remains indirect |
| Clinical Relevance | 4 | Radiotherapy planning efficiency could improve; clinical impact depends on prospective integration |
| Population Reach | 5 | All radiotherapy patients; wide but indirect |
| Implementation Speed | 4 | Requires integration into planning systems; regulatory clearance; vendor partnership |
| Evidence Strength | 6 | Held-out test cohort (n=498 plans); multicenter training; challenge benchmark provides external reference |
Main limitation: Challenge metric ≠ clinical outcome; no patient-level validation. Evidence Maturity: Exploratory — technically promising, clinically unproven.
Article 14 — Liso-cel vs. Axi-cel Care Pathways, France (PMID 42950111)
⬜ STANDARD | Retrospective national hospital claims cohort | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CAR-T safety profile differences between axi-cel and liso-cel are known from trials; real-world French data adds confirmation |
| Clinical Relevance | 7 | ICU admission rates and rehospitalization are major drivers of CAR-T cost and patient burden — directly relevant to product selection |
| Population Reach | 5 | LBCL second-line CAR-T population; growing but specific |
| Implementation Speed | 6 | Both products already available; findings could influence formulary and clinical preference decisions |
| Evidence Strength | 6 | n=823 from 32 centers; national claims; retrospective; no efficacy outcomes; classification_confidence = medium |
Key quantitative result: Liso-cel → fewer ICU admissions, less tocilizumab use, fewer 3-month rehospitalizations vs. axi-cel. Main limitation: No OS or PFS data; potential patient selection differences between products not fully adjustable. Evidence Maturity: Validated (real-world safety); no efficacy comparison.
Article 15 — Explainable Blood Cell Classification (Cross-Modal AI) (PMID 42950648)
⬜ STANDARD | ML development and clinician evaluation | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Cross-modal explanation framework for blood cell AI is methodologically novel; explainability is increasingly important for clinical AI |
| Clinical Relevance | 4 | Clinician trust in AI explanation is a precursor to adoption; not yet at patient-outcome level |
| Population Reach | 5 | Hematology labs globally; broad potential if adopted |
| Implementation Speed | 4 | Requires clinical validation, regulatory clearance, and workflow integration |
| Evidence Strength | 4 | N=12 clinicians for user evaluation; image dataset sizes unreported; internal validation only; classification_confidence = medium |
Key quantitative result: Mean clinician reasoning score 4.46/5; cross-modal explanations outperformed Grad-CAM alignment. Evidence Maturity: Exploratory.
Article 16 — Arginine Rescue of Fever-Induced CAR-T Dysfunction (PMID 42950831)
⚪ PROMISING_PRELIMINARY | Translational + preclinical | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Mechanistic link between fever → eIF4F translation → CAR-T dysfunction, and arginine rescue is genuinely novel and published in Cell Metabolism |
| Clinical Relevance | 4 | Mixed-species study; human clinical correlation is retrospective and associative only; cannot exceed 5 for non-human primary results |
| Population Reach | 5 | All CAR-T recipients; broad if mechanism generalizes |
| Implementation Speed | 3 | Requires clinical trials to establish safety and dosing of arginine in CAR-T patients |
| Evidence Strength | 4 | Preclinical primary evidence; retrospective human correlation; no sample size reported; classification_confidence = medium |
Key quantitative result: High-grade fever correlated with poorer CAR-T response; arginine restored function in experimental systems. Main limitation: Mixed-species; arginine dosing in humans is not established for this indication; abstract only. Evidence Maturity: Exploratory — mechanistically important watchlist item.
Article 17 — Sex Differences in Long-Term Care Dependency, Japan (PMID 42950852)
⬜ STANDARD | Repeated cross-sectional administrative study | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Age-sex patterns in LTC dependency are known; reversal of sex dominance at oldest ages is a useful confirmation |
| Clinical Relevance | 4 | Population planning relevance; not directly patient-care-changing |
| Population Reach | 7 | Globally aging population; elderly women specifically underrepresented in care planning |
| Implementation Speed | 5 | Policy-level change; moderate lead time |
| Evidence Strength | 6 | Very large dataset (~400,000); 6-year longitudinal administrative data; Japan-specific; classification_confidence = medium |
Evidence Maturity: Validated (administrative) for descriptive epidemiology.
Article 18 — AI Prediction of Long-Term Care Dependency (PMID 42950853)
⬜ STANDARD | ML development and internal validation | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Explainable ML for LTC dependency prediction is incremental; SHAP-based interpretability adds some value |
| Clinical Relevance | 4 | Early identification of at-risk elderly could enable prevention; no clinical outcome validation yet |
| Population Reach | 6 | Aging populations globally; Japan-specific model |
| Implementation Speed | 4 | Internal validation only; external validation required before deployment |
| Evidence Strength | 4 | Internal validation only; no sample size in abstract; AUC 0.870 on internal test; classification_confidence = medium |
Evidence Maturity: Exploratory.
Article 19 — Speech-Based Bipolar vs. Unipolar Depression Differentiation (PMID 42951037)
⬜ STANDARD | Cross-sectional diagnostic ML study | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Speech-based differentiation of bipolar from unipolar depression is clinically important and underexplored |
| Clinical Relevance | 5 | Misdiagnosis of bipolar disorder as MDD has major treatment implications; but F1=0.643 is modest |
| Population Reach | 6 | Depression affects ~280M people globally; bipolar disorder ~45M; differentiation is a widespread clinical problem |
| Implementation Speed | 4 | Modest performance; needs larger external validation before clinical use |
| Evidence Strength | 4 | N=214; cross-sectional; no external validation; classification_confidence = medium |
Evidence Maturity: Exploratory.
Article 20 — Digital Twin for T1D Precision Care (SFDT1) (PMID 42951245)
⬜ STANDARD | Cohort phenotyping with internal validation | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Digital twin framework for T1D with reproducible subphenotypes is genuinely novel and methodologically sophisticated |
| Clinical Relevance | 4 | Conceptually compelling; not yet at point of changing individual patient management |
| Population Reach | 6 | ~8.7M adults with T1D globally |
| Implementation Speed | 3 | Early-stage; requires external validation, integration with care workflows, regulatory considerations |
| Evidence Strength | 5 | Reasonable derivation N (2,187); internal validation only (n=235); classification_confidence = medium |
Evidence Maturity: Exploratory.
Article 21 — Dual-Mode Biosensor for Autoimmune Hepatitis (PMID 42951567)
⚪ PROMISING_PRELIMINARY | Diagnostic biosensor development | Triage score: 6 | Unsolicited find
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-mode cross-validating biosensor design is novel; ANA quantification with high AUC (0.967) is impressive |
| Clinical Relevance | 5 | ANA testing is standard; point-of-care or simplified assays have value, especially in resource-limited settings |
| Population Reach | 4 | Autoimmune hepatitis is uncommon (~1–2/100,000); broader ANA utility possible |
| Implementation Speed | 3 | Lab biosensor → clinical assay pathway is long |
| Evidence Strength | 4 | n=160 clinical samples; no external validation; classification_confidence = medium |
Evidence Maturity: Exploratory.
Article 22 — Migrant Health Screening Education, Australia (PMID 42949310)
🟡 UNDERSERVED_POPULATION | Community quality-improvement | Triage score: 5 | Unsolicited find
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Culturally tailored education improving health knowledge is well-established; this is implementation data |
| Clinical Relevance | 5 | Knowledge improvement is a prerequisite for screening uptake; no behavior or health outcome data |
| Population Reach | 6 | Migrants and refugees globally are systematically underserved; scalable if replicable |
| Implementation Speed | 7 | Low-cost, low-technology intervention; replicable with community health infrastructure |
| Evidence Strength | 4 | Pre-post without control; n=301 paired questionnaires; classification_confidence = medium |
Evidence Maturity: Exploratory.
Article 23 — Soybean Polysaccharide and Vascular Aging in Mice (PMID 42949332)
⚪ PROMISING_PRELIMINARY | Preclinical mouse study | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Gut-vascular axis / PPARγ-P21-butyrate pathway in aging endothelium is mechanistically interesting |
| Clinical Relevance | 2 | Animal study; cannot exceed 5; human translation is speculative |
| Population Reach | 2 | Preclinical only |
| Implementation Speed | 1 | Lab stage |
| Evidence Strength | 3 | Animal model; no sample size reported; abstract only |
Evidence Maturity: Exploratory (preclinical).
Article 24 — TRACER: Cell-Line to Patient Tumor Drug Response Transfer (PMID 42949538)
⚪ PROMISING_PRELIMINARY | Computational model | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Cross-domain alignment of pharmacogenomic models while preserving response labels is methodologically novel |
| Clinical Relevance | 2 | In vitro computational; requires extensive functional and clinical validation |
| Population Reach | 2 | Preclinical/computational stage |
| Implementation Speed | 1 | Lab/computational |
| Evidence Strength | 3 | Internal validation only; no sample size; in vitro |
Evidence Maturity: Exploratory.
Article 25 — Ionic Liquid Whole-Tumor-Cell Vaccines in Melanoma Mice (PMID 42949972)
⚪ PROMISING_PRELIMINARY | Preclinical vaccine study | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Ionic liquid cellular loading for whole-tumor-cell vaccine manufacturing is technically novel; PNAS venue supports rigor |
| Clinical Relevance | 2 | Animal model only; cannot exceed 5 |
| Population Reach | 2 | Preclinical |
| Implementation Speed | 1 | Lab stage |
| Evidence Strength | 3 | Mouse model; no sample size |
Evidence Maturity: Exploratory (preclinical).
Article 26 — Intratumoral Microbiota Epitopes for Pan-Cancer Immunotherapy (PMID 42950024) (Note: DOI in article 27 field; this is PMID 42950024)
⚪ PROMISING_PRELIMINARY | Pan-cancer computational + preclinical | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Pan-cancer microbiota-derived epitopes as vaccine/immunotherapy targets is conceptually bold and broadly novel |
| Clinical Relevance | 3 | Mixed-species; cross-reactive T-cell responses in experimental systems; human clinical relevance unestablished |
| Population Reach | 3 | 24 cancer types screened; broad conceptual reach but preclinical |
| Implementation Speed | 1 | Multiple steps from epitope identification to clinical vaccine |
| Evidence Strength | 4 | Computational + experimental validation; 1,190 tumor samples; no human trial data |
Evidence Maturity: Exploratory.
Article 27 — PSAT1 and Ferroptosis Resistance in Hepatocellular Carcinoma (PMID 42950043)
⚪ PROMISING_PRELIMINARY | Preclinical + patient tumor association | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | PSAT1 as a dual regulator of ferroptosis and immune evasion in HCC is a novel mechanistic finding |
| Clinical Relevance | 3 | Mixed-species; no clinical trial data |
| Population Reach | 3 | HCC is the 3rd leading cause of cancer death; preclinical stage |
| Implementation Speed | 1 | Preclinical |
| Evidence Strength | 4 | Preclinical + patient tumor correlations; no sample sizes |
Evidence Maturity: Exploratory.
Article 28 — AI Facial Aging Grading (PMID 42950221)
⬜ STANDARD | Algorithm development, internal evaluation | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | AI facial aging grading tools exist; this adds standardization |
| Clinical Relevance | 3 | Limited clinical application vs. research/cosmetic use |
| Population Reach | 3 | North American women only; limited generalizability |
| Implementation Speed | 4 | Technically feasible; clinical utility narrow |
| Evidence Strength | 4 | Internal validation only (n=468); no external cohort |
Evidence Maturity: Exploratory.
Article 29 — Web-Based DASH + Mindful Eating Pilot RCT (PMID 42950223)
⬜ STANDARD | Pilot RCT | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | DASH + mindful eating is not new; web-based delivery adds modest novelty |
| Clinical Relevance | 4 | Feasibility only; no clinical cardiometabolic improvement in this small pilot |
| Population Reach | 6 | Working adults at CV risk; broadly relevant population |
| Implementation Speed | 5 | Web-based; scalable if proven effective |
| Evidence Strength | 4 | n=37; pilot; underpowered for clinical outcomes |
Evidence Maturity: Exploratory.
Article 30 — Pharmacist-Led HF Medication Optimization Pilot (PMID 42950309)
⬜ STANDARD | Pilot RCT (failed feasibility) | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Pharmacist-led optimization is established; this confirms infeasibility of current design |
| Clinical Relevance | 4 | Negative feasibility finding is informative for trial design; not directly practice-changing |
| Population Reach | 6 | HFrEF is common (~26M globally) |
| Implementation Speed | 2 | Major redesign required before any trial |
| Evidence Strength | 5 | Explicit feasibility criteria (11 defined); only 1/11 met — rigorous and honest reporting |
Evidence Maturity: Exploratory (feasibility failure).
Article 31 — Indian Colorectal Cancer Genomic Profiling (PMID 42950362)
⬜ STANDARD | Exploratory genomic cohort | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Population-specific CRC genomics in underrepresented South Asian cohort has equity value; n=20 tumors severely limits conclusions |
| Clinical Relevance | 3 | Hypothesis-generating only at n=20 |
| Population Reach | 5 | India has large CRC burden; population-specific data needed |
| Implementation Speed | 2 | Requires much larger validation cohort |
| Evidence Strength | 3 | n=20 tumors; no external validation |
Evidence Maturity: Exploratory.
Article 32 — Inverse-Probability Weighting for Real-World PFS (PMID 42950850)
⬜ STANDARD | Statistical methods study | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ISP weighting for left-truncated genomic data is methodologically useful for real-world evidence generation |
| Clinical Relevance | 3 | Methods paper; indirect clinical impact |
| Population Reach | 3 | Methodologists and trial designers; indirect |
| Implementation Speed | 4 | Methods can be adopted in future studies |
| Evidence Strength | 5 | Simulations + real-world demonstration; no external validation of method performance |
Evidence Maturity: Exploratory.
Article 33 — Wiskott-Aldrich Syndrome Gene Therapy — EMA Perspective (PMID 42950981)
⬜ STANDARD | Regulatory review | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First approved gene therapy for WAS; regulatory milestone |
| Clinical Relevance | 7 | For WAS patients — a severe, life-limiting X-linked immunodeficiency — this is practice-changing; judged relative to unmet need |
| Population Reach | 3 | Ultra-rare: ~1–10/million male births |
| Implementation Speed | 5 | Already approved in EU; implementation now underway, but access globally is limited |
| Evidence Strength | 4 | Regulatory review summary only; no primary data in abstract; classification_confidence = medium |
Note: Relative to its population, this rivals Article 2 in importance. Scored conservatively on population reach given ultra-rare designation. Could be elevated if WAS context is prioritized. Evidence Maturity: Validated (regulatory approval reached).
Article 34 — AI for Aortic Aneurysm Imaging — Scoping Review (PMID 42951185)
⬜ STANDARD | Scoping review | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Scoping review confirms existing knowledge; no new findings |
| Clinical Relevance | 4 | Highlights validation gap; informative for researchers |
| Population Reach | 5 | Aortic aneurysm affects ~3% of adults >65 |
| Implementation Speed | 3 | Clinical integration remains premature per review's own conclusion |
| Evidence Strength | 5 | 59 studies reviewed; scoping methodology; abstract only |
Evidence Maturity: Exploratory (review).
Article 35 — Exome Sequencing Reanalysis — Narrative Review (PMID 42951338)
⬜ STANDARD | Narrative review | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Reanalysis value is established; this synthesizes best practices |
| Clinical Relevance | 5 | Actionable for clinical genetics labs; identifies additional diagnoses for unresolved patients |
| Population Reach | 5 | Rare disease patients with nondiagnostic exome; globally millions await diagnosis |
| Implementation Speed | 5 | Labs can implement structured reanalysis workflows now |
| Evidence Strength | 4 | Narrative review; no original data |
Evidence Maturity: Exploratory (review).
Article 36 — DLL3-Directed Therapeutics in SCLC — Review (PMID 42951714)
⬜ STANDARD | Narrative review | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | DLL3 landscape review synthesizes active area; tarlatamab and other agents are clinically active |
| Clinical Relevance | 5 | SCLC has very limited options; DLL3-directed therapies are genuinely promising |
| Population Reach | 6 | ~250,000 SCLC cases/year globally; uniformly poor prognosis |
| Implementation Speed | 4 | Comparative evidence still developing |
| Evidence Strength | 3 | Narrative review; no primary data |
Evidence Maturity: Exploratory.
Article 37 — Inherited Anemias: Diagnosis and Treatment Review (PMID 42951621)
⬜ STANDARD | Narrative review | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Synthesis of current approaches; no new findings |
| Clinical Relevance | 4 | Useful clinical reference for hematologists |
| Population Reach | 5 | Inherited anemias (sickle cell, thalassemia, etc.) affect millions globally |
| Implementation Speed | 4 | Review of existing approaches |
| Evidence Strength | 3 | Narrative review; abstract only |
Evidence Maturity: Exploratory.
Article 38 — [French Chlamydia Screening (Article 6 duplicate — correctly Article 6 above)]
(Already scored above as Article 6 / PMID 42950355)